Ahmet ULUŞAN, Seval KUL, Kemal BAKIR, Ahmet Feridun IŞIK, Miray ERSÖZ, Levent ELBEYLİ, Bülent TUNÇÖZGÜR, Maruf ŞANLI

Ameliyat edilmiş T3 küçük hücre dışı akciğer kanserinde prognostik faktörler: 129 hastalık retrospektif, tek merkezli çalışma

Amaç: Bu çalışmada cerrahi geçiren T3 küçük hücre dışı akciğer kanserli hastalarda sağkalım oran ve sürelerini etkileyen prognostik faktörler araştırıldı. Çalışma planı: Kliniğimizde Ocak 1997 - Aralık 2013 tarihleri arasında cerrahi uygulanan T3 küçük hücre dışı akciğer kanserli 129 hasta (125 erkek, 4 kadın; ort. yaş 60±9.3 yıl; dağılım 23-80 yıl) yaş, cinsiyet, rezeksiyon tipi, tümör histopatolojisi, tümör, nod ve metastaz evresi, lenf nodu tutulumu, kemoterapi ve radyoterapi ile nüks durumu açısından retrospektif olarak incelendi. Bulgular: Değerlendirme sırasında 61 hasta (%47.3) sağ iken 68’i (%52.7) hayatını kaybetmişti. Çalışma popülasyonunun bir, iki ve beş yıllık sağkalım oranları sırasıyla %79.8, %56.9 ve %23.2 idi. Ortalama sağkalım süresi 41.5±4.0 ay (dağılım 33.7-49.4 ay) idi. Hasta yaşı ve tümör histopatolojisi sağkalım süresini etkilemedi. Genel sağkalım süresi evre IIB hastalarında, düşük lenf nodu tutulum evresine sahip hastalarda, lobektomi uygulananlarda, kemoterapi veya radyoterapi alanlarda ve nüks olmayanlarda anlamlı olarak daha uzundu (her biri için p

Prognostic factors in operated T3 non-small cell lung cancer: A retrospective, single-center study of 129 patients

Background: This study aims to investigate the prognostic factors that affect survival rates and durations in patients with T3 non-small cell lung cancer who underwent surgery.Methods: A total of 129 patients with T3 non-small cell lung cancer (125 males, 4 females; mean age 60±9.3 years; range 23 to 80 years) who were performed surgery in our clinic between January 1997 and December 2013 were evaluated retrospectively in terms of age, gender, type of resection, tumor histopathology, tumor, node and metastasis staging, lymph node invasion, chemotherapy and radiotherapy, and recurrence.Results: During the evaluation, while 61 patients (47.3%) were alive, 68 (52.7%) had lost their lives. One-, two- and five-year survival rates of the study population were 79.8%, 56.9% and 23.2%, respectively. Mean duration of survival was 41.5±4.0 months (range 33.7-49.4 months). Patient’s age or tumor histopathology did not affect the duration of survival. Overall duration of survival was significantly longer in patients of stage IIB, patients who had low stages of lymph node invasion, who were performed lobectomy, who received chemotherapy or radiotherapy or who were without recurrence (p

PDF

___

26. Choi PJ, Jeong SS1, Yoon SS1. Prognosis of recurrence after complete resection in early-stage non-small cell lung cancer. Korean J Thorac Cardiovasc Surg 2013;46:449-56.
25. Arriagada R, Bergman B, Dunant A, Le Chevalier T, Pignon JP, Vansteenkiste J. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N Engl J Med 2004;350:351-60.
24. Albain KS, Rusch VW, Crowley JJ, Rice TW, Turrisi AT, Weick JK, et al. Concurrent cisplatin/etoposide plus chest radiotherapy followed by surgery for stages IIIA (N2) and IIIB non-small-cell lung cancer: mature results of Southwest Oncology Group phase II study 8805. J Clin Oncol 1995;13:1880-92.
23. Spiro SG, Rudd RM, Souhami RL, Brown J, Fairlamb DJ, Gower NH, et al. Chemotherapy versus supportive care in advanced non-small cell lung cancer: improved survival without detriment to quality of life. Thorax 2004;59:828-36.
22. Martini N, Bains MS, Burt ME, Zakowski MF, McCormack P, Rusch VW, et al. Incidence of local recurrence and second primary tumors in resected stage I lung cancer. J Thorac Cardiovasc Surg 1995;109:120-9.
21. Winton T, Livingston R, Johnson D, Rigas J, Johnston M, Butts C, et al. Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer. N Engl J Med 2005;352:2589-97.
20. Wang J, Wu N, Zheng Q, Feng Y, Yan S, Lv C, et al. Evaluation of the 7th edition of the TNM classification for lung cancer at a single institution. J Cancer Res Clin Oncol 2014;140:1189-95.
19. Saha SP, Kalathiya RJ, Davenport DL, Ferraris VA, Mullett TW, Zwischenberger JB. Survival after Pneumonectomy for Stage III Non-small Cell Lung Cancer. Oman Med J 2014;29:24-7.
18. Iyoda A, Hiroshima K, Moriya Y, Yoshida S, Suzuki M, Shibuya K, et al. Predictors of postoperative survival in patients with locally advanced non-small cell lung carcinoma. Surg Today 2010;40:725-8.
17. Takenaka T, Katsura M, Shikada Y, Takeo S. Outcome of surgical resection as a first line therapy in T3 non-small cell lung cancer patients. World J Surg 2013;37:2574-80.
16. Sonobe M, Yamada T, Sato M, Menju T, Aoyama A, Sato T, et al. Identification of subsets of patients with favorable prognosis after recurrence in completely resected non-small cell lung cancer. Ann Surg Oncol 2014;21:2546-54.
15. Suzuki M, Yoshida S, Moriya Y, Hoshino H, Mizobuchi T, Okamoto T, et al. Surgical outcomes of newly categorized peripheral T3 non-small cell lung cancers: comparisons between chest wall invasion and large tumors (>7 cm). Interact Cardiovasc Thorac Surg 2010;11:420-4.
14. Turna A, Karamustafaoğlu A, Solak O, Metin M, Ürer N, Bedirhan MA, et al. The effect of localization on survival of the patients with resected T3 non-small cell lung cancer. Eurasian J Pulmonol 2003;5:207-12.
13. Sanli M, Isik AF, Zincirkeser S, Elbek O, Mete A, Tuncozgur B, et al. Reliability of positron emission tomography-computed tomography in identification of mediastinal lymph node status in patients with non-small cell lung cancer. J Thorac Cardiovasc Surg 2009;138:1200-5.
12. Akpinar D, Ceylan KC, Duman E, Unsal S, Kaya SO. The accuracy of positron emission tomography in mediastinal staging of non-small cell lung cancer. Turk Gogus Kalp Dama 2013;21:100-5.
11. Riquet M, Lang-Lazdunski L, Le PB, Dujon A, Souilamas R, Danel C, et al. Characteristics and prognosis of resected T3 non-small cell lung cancer. Ann Thorac Surg 2002;73:253-8.
10. Duzgun Y, Saygi A, Levent E, Yilmaz HO, Koksal H, Soylu AC, et al. Comparison of the sixth and seventh editions of the TNM staging systems with regard to non-small cell lung carcinoma. Turk Gogus Kalp Dama 2012;20:536-43.
9. Toker A, Isitmangil T, Erdik O, Sancakli I, Sebit S. Analysis of chest injuries sustained during the 1999 Marmara earthquake. Surg Today 2002;32:769-71.
8. Rami-Porta R, Crowley JJ, Goldstraw P. The revised TNM staging system for lung cancer. Ann Thorac Cardiovasc Surg 2009;15:4-9.
7. Vansteenkiste J, De Ruysscher D, Eberhardt WE, Lim E, Senan S, Felip E, et al. Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2013;24:89-98.
6. Arriagada R, Auperin A, Burdett S, Higgins JP, Johnson DH, Le Chevalier T, et al. Adjuvant chemotherapy, with or without postoperative radiotherapy, in operable non-small-cell lung cancer: two meta-analyses of individual patient data. Lancet 2010;375:1267-77.
5. Yan TD, Black D, Bannon PG, McCaughan BC. Systematic review and meta-analysis of randomized and nonrandomized trials on safety and efficacy of video-assisted thoracic surgery lobectomy for early-stage non-small-cell lung cancer.
4. Yue D, Gong L, You J, Su Y, Zhang Z, Zhang Z, et al. Survival analysis of patients with non-small cell lung cancer who underwent surgical resection following 4 lung cancer resection guidelines. BMC Cancer 2014;14:422.
3. Ries LAG, Eisner MP, Kosary CL, Hankey BF, Miller BA, Clegg L, et al. Cancer Statistics Review, 1975-2002. Bethesda, MD: National Cancer Institute; 2005. Available from: http://seer.cancer.gov/csr/ 1975_2007/index.html
2. TC Sağlık Bakanlığı. Türk Halk Sağlığı Kurumu. Kanser Daire Başkanlığı. Türkiye Kanser İstatistikleri. Available from: http://kanser.gov.tr/Dosya/ca_istatistik/Turkiye_ Kanser_istatistikleri.pdf Available from: http://kanser.gov.tr/ Dosya/ca_istatistik/2009kanseraporu.pdf
1. Fitzmaurice C, Dicker D, Pain A, Hamavid H, Moradi-Lakeh M, MacIntyre MF, et al. The Global Burden of Cancer 2013. JAMA Oncol 2015;1:505-27.